Stock WINT WINDTREE THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Windtree Therapeutics, Inc.

Equities

WINT

US97382D5014

Delayed Nasdaq
Other stock markets
 10:53:37 27/06/2024 pm IST 		5-day change 1st Jan Change
3.295 USD +2.33% Intraday chart for Windtree Therapeutics, Inc. +2.33% -74.54%
15/05 Windtree Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
17/04 Windtree Therapeutics Seeks Acquisitions CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Windtree Therapeutics : May'24 Corporate Presentation
PU
Windtree Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Windtree Therapeutics Regains Compliance with Nasdaq
AQ
Windtree Therapeutics : April'24 Corporate Presentation
PU
Reverse Split: 1 of 18
FA
Windtree Therapeutics Announces Reverse Stock Split
AQ
Windtree Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Key Business Updates
AQ
Windtree Therapeutics Seeks Acquisitions
CI
Windtree Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
North American Morning Briefing : Stock Futures -2-
DJ
Transcript : Windtree Therapeutics, Inc. - Shareholder/Analyst Call
Windtree Therapeutics to Acquire Cancer Treatment From Varian Biopharmaceuticals
MT
Windtree Acquires Early-Stage, Novel Oncology Platform and Completes $1.5 Million Convertible Note Bridge Financing
AQ
Windtree Therapeutics, Inc. announced that it has received $1.5 million in funding
CI
Windtree Therapeutics, Inc. acquired All of the assets of Varian Biopharmaceuticals, Inc.
CI
Windtree Therapeutics, Inc. announced that it expects to receive $1.5 million in funding
CI
Windtree Therapeutics, Inc. Announces Resignation of John A. Tattory as Interim Chief Financial Officer and Principal Financial Officer
CI
Windtree Therapeutics, Inc. Announces Resignation of John A. Tattory as Principal Financial Officer
CI
Windtree Renews Agreement with Chang Gung University for Scientific Collaboration to Further SERCA2a Research
AQ
Windtree Therapeutics, Inc. Renews Agreement with Chang Gung University for Scientific Collaboration to Further SERCA2a Research
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. WINT Stock
  4. News Windtree Therapeutics, Inc.